S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:BCTX

BriaCell Therapeutics (BCTX) Stock Price, News & Analysis

$2.67
+0.13 (+5.12%)
(As of 03/27/2024 ET)
Today's Range
$2.49
$2.68
50-Day Range
$2.26
$4.34
52-Week Range
$2.19
$7.75
Volume
85,183 shs
Average Volume
101,955 shs
Market Capitalization
$42.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

BriaCell Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
574.2% Upside
$18.00 Price Target
Short Interest
Healthy
5.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of BriaCell Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.79) to ($1.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

558th out of 939 stocks

Pharmaceutical Preparations Industry

259th out of 422 stocks

BCTX stock logo

About BriaCell Therapeutics Stock (NASDAQ:BCTX)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCTX Stock Price History

BCTX Stock News Headlines

BriaCell Therapeutics Corp. (BCTX)
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
BCTX: November 2023 SITC Poster
BriaCell Therapeutics Corp Ordinary Shares - New BCTX
BCTX: Year in Review
BriaCell Therapeutics Corp Ordinary Shares - New
BCTX: Pivotal Study Protocol Cleared
See More Headlines
Receive BCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/14/2023
Today
3/27/2024
Next Earnings (Estimated)
6/12/2024
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BCTX
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$18.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+574.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.52) per share

Miscellaneous

Free Float
12,503,000
Market Cap
$42.67 million
Optionable
Optionable
Beta
1.04
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. William V. Williams M.D. (Age 69)
    CEO, President & Director
    Comp: $785.3k
  • Mr. Gadi Levin B.Com. (Age 51)
    C.A., CPA, M.B.A., CFO & Corporate Secretary
    Comp: $304.46k
  • Dr. Miguel A. Lopez-Lago Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $298.9k
  • Dr. Giuseppe Del Priore M.D. (Age 62)
    M.P.H., MPH, Chief Medical Officer
    Comp: $492.5k
  • Dr. Charles Louis Wiseman FACP (Age 78)
    M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board
    Comp: $241.14k

BCTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BriaCell Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares.
View BCTX analyst ratings
or view top-rated stocks.

What is BriaCell Therapeutics' stock price target for 2024?

1 analysts have issued 12 month price objectives for BriaCell Therapeutics' stock. Their BCTX share price targets range from $18.00 to $18.00. On average, they predict the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 574.2% from the stock's current price.
View analysts price targets for BCTX
or view top-rated stocks among Wall Street analysts.

How have BCTX shares performed in 2024?

BriaCell Therapeutics' stock was trading at $5.85 at the start of the year. Since then, BCTX shares have decreased by 54.4% and is now trading at $2.67.
View the best growth stocks for 2024 here
.

Are investors shorting BriaCell Therapeutics?

BriaCell Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 733,300 shares, a drop of 7.9% from the February 29th total of 795,900 shares. Based on an average trading volume of 108,400 shares, the days-to-cover ratio is presently 6.8 days. Currently, 5.2% of the shares of the stock are short sold.
View BriaCell Therapeutics' Short Interest
.

When is BriaCell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our BCTX earnings forecast
.

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) posted its quarterly earnings results on Thursday, December, 14th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.32.

When did BriaCell Therapeutics IPO?

BriaCell Therapeutics (BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

Who are BriaCell Therapeutics' major shareholders?

BriaCell Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (1.67%), Redmond Asset Management LLC (0.84%), K.J. Harrison & Partners Inc (0.51%), Onyx Bridge Wealth Group LLC (0.19%), Royal Bank of Canada (0.12%) and National Bank of Canada FI (0.05%).
View institutional ownership trends
.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners